Skip to main content
Premium Trial:

Request an Annual Quote

Screenings Delayed

Researchers are investigating the effect of delayed cancer screenings due to the COVID-19 pandemic, the Associated Press reports.

Cancer screenings like colonoscopies, mammograms, lung scans, Pap tests, and more were put off as healthcare workers grappled with the onslaught of the pandemic. Now, as people reschedule their screenings, the AP writes that researchers are examining whether the delay has led to missed or more advanced diagnoses.

It reports that one group from the University of Cincinnati found that once lung cancer screenings started up again that 29 percent of people screened has suspicious findings, as compared to 8 percent in other years. Other researchers in the Netherlands, though, found no difference in breast cancer stages uncovered through mammograms, it says, while researchers in Boston found that just after screening resumed, the number of cancers uncovered was higher than usual, but then fell to typical levels a few months later.

The AP adds that at-home testing has also been adopted due to the pandemic.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.